Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ridaforolimus in Taxane-Resistant AIPC
NCT00110188Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- May 2005
- Primary completion
- Apr 2007
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ridaforolimus in prostate cancer (PCa), sponsored by Merck & Co. Primary endpoint: Best Overall Response (BOR) per RECIST up to 24 months. Started May 2005; status: completed.
02
Drugs
ridaforolimus
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00110188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00110188.